裕同科技(002831.SZ):第二期員工持股計劃股票鎖定期於3月15日屆滿
格隆匯3月14日丨裕同科技(002831.SZ)公佈,公司第二期員工持股計劃股票鎖定期於2022年3月15日屆滿。
截止2021年3月15日,公司第二期員工持股計劃(陝國投·裕同科技第二期員工持股集合資金信託計劃、陝國投·裕同科技第二期2號員工持股集合資金信託計劃)通過二級市場以大宗交易以及集中競價的方式累計買入公司股票2085.0177萬股,佔公司總股本的2.22%,成交總金額約6.55億元(不含交易費用),成交均價31.42元/股。最後一筆於2021年3月15日買入,公司已按規定於公司股東大會審議通過後6個月內完成第二期員工持股計劃標的股票的購買。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.